Literature DB >> 9644707

Changing i.v. administration sets: is 48 versus 24 hours safe for neutropenic patients with cancer?

D deMoissac1, L Jensen.   

Abstract

PURPOSE/
OBJECTIVES: To examine the effects of changing i.v. administration sets at 48 versus 24 hours on the incidence of infusion-related septicemia in neutropenic patients with cancer.
DESIGN: Prospective, randomized clinical trial with repeated measures.
SETTING: Large urban cancer center. SAMPLE: 50 adult inpatients with a primary diagnosis of hematologic malignancy, breast cancer, or testicular cancer or who were receiving a stem cell transplant.
METHOD: Subjects were assigned randomly to have their i.v. sets changed every 48 or 24 hours. Subjects continued in the study for a maximum of five measurements, until they were no longer neutropenic, or until transferred or discharged from the hospital. MAIN RESEARCH VARIABLES: Rates of infusate colonization, microorganisms identified, incidence of infusion-related septicemia.
FINDINGS: Colonized infusate was detected in 18 (5%) of 413 i.v. sets; 9 (5%) of 177 sets were changed at 48 hours, and 9 (4%) of 236 sets were changed at 24 hours (p > 0.05). A trend toward increased colonization of i.v. sets used to administer parenteral nutrition (19%) and, to a lesser extent, electrolytes (9%) was identified in the 48-hour group. Coagulase-negative staphylococci were the most frequently isolated microorganisms in the i.v. infusate. Similar organisms were isolated from blood cultures and administration sets, however, no subject had identical organisms isolated from both i.v. infusate and blood cultures. No subject with colonized infusate developed infusion-related septicemia.
CONCLUSIONS: No difference existed in the incidence of colonization or infusion-related septicemia between subjects whose i.v. administration sets were changed at 48 versus 24 hours. IMPLICATIONS FOR NURSING PRACTICE: Changing i.v. administration sets every 48 hours is recommended. Exceptions to this include i.v. administration sets used to administer blood products and total parenteral nutrition.

Entities:  

Mesh:

Year:  1998        PMID: 9644707

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  2 in total

Review 1.  Optimal timing for intravascular administration set replacement.

Authors:  Amanda J Ullman; Marie L Cooke; Donna Gillies; Nicole M Marsh; Azlina Daud; Matthew R McGrail; Elizabeth O'Riordan; Claire M Rickard
Journal:  Cochrane Database Syst Rev       Date:  2013-09-15

2.  Intravascular device administration sets: replacement after standard versus prolonged use in hospitalised patients-a study protocol for a randomised controlled trial (The RSVP Trial).

Authors:  Claire M Rickard; Nicole M Marsh; Joan Webster; Nicole C Gavin; Matthew R McGrail; Emily Larsen; Amanda Corley; Debbie Long; John R Gowardman; Marghie Murgo; John F Fraser; Raymond J Chan; Marianne C Wallis; Jeanine Young; David McMillan; Li Zhang; Md Abu Choudhury; Nicholas Graves; E Geoffrey Playford
Journal:  BMJ Open       Date:  2015-02-03       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.